PYRGF vs. AQST, ATXS, ANNX, ADCT, PROK, RZLT, SLRN, AARD, BTMD, and MNPR
Should you be buying PyroGenesis Canada stock or one of its competitors? The main competitors of PyroGenesis Canada include Aquestive Therapeutics (AQST), Astria Therapeutics (ATXS), Annexon (ANNX), ADC Therapeutics (ADCT), ProKidney (PROK), Rezolute (RZLT), Acelyrin (SLRN), Aardvark Therapeutics (AARD), biote (BTMD), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry.
PyroGenesis Canada vs.
Aquestive Therapeutics (NASDAQ:AQST) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, community ranking, analyst recommendations, institutional ownership and risk.
In the previous week, Aquestive Therapeutics had 16 more articles in the media than PyroGenesis Canada. MarketBeat recorded 18 mentions for Aquestive Therapeutics and 2 mentions for PyroGenesis Canada. PyroGenesis Canada's average media sentiment score of 0.31 beat Aquestive Therapeutics' score of 0.26 indicating that PyroGenesis Canada is being referred to more favorably in the news media.
Aquestive Therapeutics received 217 more outperform votes than PyroGenesis Canada when rated by MarketBeat users.
Aquestive Therapeutics has a net margin of -59.75% compared to PyroGenesis Canada's net margin of -115.14%.
32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 8.4% of Aquestive Therapeutics shares are held by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Aquestive Therapeutics has higher revenue and earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aquestive Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Aquestive Therapeutics presently has a consensus price target of $10.67, suggesting a potential upside of 369.90%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Aquestive Therapeutics is more favorable than PyroGenesis Canada.
Summary
Aquestive Therapeutics beats PyroGenesis Canada on 12 of the 16 factors compared between the two stocks.
Get PyroGenesis Canada News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYRGF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PYRGF vs. The Competition
PyroGenesis Canada Competitors List
Related Companies and Tools
This page (NASDAQ:PYRGF) was last updated on 5/21/2025 by MarketBeat.com Staff
